Skip to main content
. 2017 Feb 8;8(11):18129–18144. doi: 10.18632/oncotarget.15185

Figure 6. Inhibition of tumor cell growth and metastatic ability by rapamycin or cardamonin.

Figure 6

A. Growth inhibition of OIP5 transfectants treated with rapamycin (RPM, 100 nM), cardamonin (CDM, 10 μM), or vehicle (Veh). Cell growth was measured by MTT assay five days after the cells were seeded on 24-well plates (2 × 104 cells/well). Each value represents the mean ± SD. **P < 0.01. B. A wound healing assay demonstrated substantial inhibition of OIP5-mediated wound closure by RPM (100 nM) or CDM (10 μM) (upper panels). Quantitative measurements are shown (lower panels). Each bar represents the mean ± SD (n = 3). **P < 0.01. C. A Matrigel assay showed that the invasiveness of OIP5 transfectants was inhibited by CDM (10 μM), but less so by RPM (100 nM) or vehicle (upper panels). Quantitative measurements are shown (lower panels). Each bar represents the mean ± SD (n = 3). **P < 0.01. D. Change in EMT marker protein expression by treatment with either RPM or CDM in HLK3 cells transiently infected with Ad-OIP5 or Ad-LacZ adenovirus (n = 3).